Griffith TS - Search Results

1

Therapeutic applications of TRAIL receptor agonists in cancer and beyond.

Amarante-Mendes GP, Griffith TS. Amarante-Mendes GP, et al. Among authors: griffith ts. Pharmacol Ther. 2015 Nov;155:117-31. doi: 10.1016/j.pharmthera.2015.09.001. Epub 2015 Sep 5. Pharmacol Ther. 2015. PMID: 26343199 Free PMC article. Review.

2

The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis.

Griffith TS, Kemp TJ. Griffith TS, et al. Cancer Chemother Pharmacol. 2003 Sep;52(3):175-84. doi: 10.1007/s00280-003-0656-2. Epub 2003 Jun 14. Cancer Chemother Pharmacol. 2003. PMID: 12811515

3

TRAIL gene therapy: from preclinical development to clinical application.

Griffith TS, Stokes B, Kucaba TA, Earel JK Jr, VanOosten RL, Brincks EL, Norian LA. Griffith TS, et al. Curr Gene Ther. 2009 Feb;9(1):9-19. doi: 10.2174/156652309787354612. Curr Gene Ther. 2009. PMID: 19275567 Free PMC article. Review.

4

Induction of tumor cell apoptosis by TRAIL gene therapy.

Griffith TS. Griffith TS. Methods Mol Biol. 2009;542:315-34. doi: 10.1007/978-1-59745-561-9_17. Methods Mol Biol. 2009. PMID: 19565910

5

TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies.

Holoch PA, Griffith TS. Holoch PA, et al. Among authors: griffith ts. Eur J Pharmacol. 2009 Dec 25;625(1-3):63-72. doi: 10.1016/j.ejphar.2009.06.066. Epub 2009 Oct 18. Eur J Pharmacol. 2009. PMID: 19836385 Free PMC article. Review.

6

PMN and anti-tumor immunity--the case of bladder cancer immunotherapy.

Brincks EL, Risk MC, Griffith TS. Brincks EL, et al. Among authors: griffith ts. Semin Cancer Biol. 2013 Jun;23(3):183-9. doi: 10.1016/j.semcancer.2013.02.002. Epub 2013 Feb 11. Semin Cancer Biol. 2013. PMID: 23410637 Review.

7

Effective TRAIL-based immunotherapy requires both plasmacytoid and CD8α dendritic cells.

James BR, Brincks EL, Kucaba TA, Boon L, Griffith TS. James BR, et al. Among authors: griffith ts. Cancer Immunol Immunother. 2014 Jul;63(7):685-97. doi: 10.1007/s00262-014-1548-5. Epub 2014 Apr 8. Cancer Immunol Immunother. 2014. PMID: 24711083 Free PMC article.

8

CpG-mediated modulation of MDSC contributes to the efficacy of Ad5-TRAIL therapy against renal cell carcinoma.

James BR, Anderson KG, Brincks EL, Kucaba TA, Norian LA, Masopust D, Griffith TS. James BR, et al. Among authors: griffith ts. Cancer Immunol Immunother. 2014 Nov;63(11):1213-27. doi: 10.1007/s00262-014-1598-8. Epub 2014 Aug 21. Cancer Immunol Immunother. 2014. PMID: 25143233 Free PMC article.

9

Triptolide enhances the tumoricidal activity of TRAIL against renal cell carcinoma.

Brincks EL, Kucaba TA, James BR, Murphy KA, Schwertfeger KL, Sangwan V, Banerjee S, Saluja AK, Griffith TS. Brincks EL, et al. Among authors: griffith ts. FEBS J. 2015 Dec;282(24):4747-4765. doi: 10.1111/febs.13532. Epub 2015 Oct 18. FEBS J. 2015. PMID: 26426449 Free PMC article.

10

Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy.

Kim H, Niu L, Larson P, Kucaba TA, Murphy KA, James BR, Ferguson DM, Griffith TS, Panyam J. Kim H, et al. Among authors: griffith ts. Biomaterials. 2018 May;164:38-53. doi: 10.1016/j.biomaterials.2018.02.034. Epub 2018 Feb 17. Biomaterials. 2018. PMID: 29482062

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

199 results

Search Page

Filters